ClinicalTrials.gg
CompletedNCT03417778Updated Jan 15, 2021Results posted

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

A Phase 1 interventional study of Filgotinib in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
17th of 17
20 · median 287
Started
2018
the only one that year
Phase 1
2 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
5 of 17
Gilead Sciences

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1, and was the 10th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Eligible individuals will be male and nonpregnant, nonlactating females, aged 18 to 70 years (inclusive), (BMI) between 18 and 36 kg/m\^2 (inclusive), with either impaired hepatic function or normal hepatic function.
  • Individuals will be current nonsmokers (no use of tobacco, nicotine-containing, or tetrahydrocannabinol [THC]-containing products within the last 14 days).
  • Individuals with hepatic impairment will be categorized by the -Turcotte (CPT) classification system indicating hepatic impairment as follows:

    • Class A (mild): CPT score 5-6
    • Class B (moderate): CPT score 7-9
    • Class C (severe): CPT score 10-15
  • Hepatic impairment must have been stable during the 3 months (90 days) prior to study drug. Each individual in the control group will be matched to a individual with impaired hepatic function by age (± 10 years), gender, and body mass index (± 15%).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.

    Drug: Filgotinib

  • Experimental
    Severe Hepatic Impairment

    Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.

    Drug: Filgotinib

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.

    Drug: Filgotinib

Interventions

  • 100 mg tablet administered orally

    Also known as: GS-6034, GLPG0634

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUClast of Filgotinib

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

  2. PK Parameter: AUClast of GS-829845

    AUClast is defined as the concentration of drug from time zero to the last observable concentration. GS-829845 is the primary metabolite of filgotinib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

  3. PK Parameter: AUCinf of Filgotinib

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

  4. PK Parameter: AUCinf of GS-829845

    AUCinf is defined as the concentration of drug extrapolated to infinite time. GS-829845 is the primary metabolite of filgotinib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

  5. PK Parameter: Cmax of Filgotinib

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

  6. PK Parameter: Cmax of GS-829845

    Cmax is defined as the maximum observed concentration of drug. GS-829845 is the primary metabolite of filgotinib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1

Secondary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events

    Time frame: Day 1 up to Day 31

  2. Percentage of Participants Who Experienced Graded Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Day 1 up to Day 31

07

Results

Posted Jan 15, 2021

Participant flow

Participants were enrolled at study sites in Germany, New Zealand, and United States. The first participant was screened on 03 April 2018. The last study visit occurred on 09 August 2018.

Participant flow — Overall Study
MilestoneModerate Hepatic ImpairmentHealthy Control
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUClast of Filgotinib

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUClast of Filgotinib
h*ng/mLModerate Hepatic ImpairmentHealthy Control
Pharmacokinetic (PK) Parameter: AUClast of Filgotinib2389.3 ± 530.851981.9 ± 995.78
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 161.14 · 90% CI 80.77 to 321.48
PrimaryPK Parameter: AUClast of GS-829845

AUClast is defined as the concentration of drug from time zero to the last observable concentration. GS-829845 is the primary metabolite of filgotinib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of GS-829845
h*ng/mLModerate Hepatic ImpairmentHealthy Control
PK Parameter: AUClast of GS-82984532466.8 ± 10898.8531412.6 ± 13758.34
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 122.08 · 90% CI 69.67 to 213.89
PrimaryPK Parameter: AUCinf of Filgotinib

AUCinf is defined as the concentration of drug extrapolated to infinite time.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUCinf of Filgotinib
h*ng/mLModerate Hepatic ImpairmentHealthy Control
PK Parameter: AUCinf of Filgotinib2417.0 ± 533.741995.9 ± 997.88
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 159.15 · 90% CI 82.22 to 308.06
PrimaryPK Parameter: AUCinf of GS-829845

AUCinf is defined as the concentration of drug extrapolated to infinite time. GS-829845 is the primary metabolite of filgotinib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUCinf of GS-829845
h*ng/mLModerate Hepatic ImpairmentHealthy Control
PK Parameter: AUCinf of GS-82984533296.5 ± 11568.3332060.0 ± 14329.57
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 122.32 · 90% CI 69.90 to 214.07
PrimaryPK Parameter: Cmax of Filgotinib

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Filgotinib
ng/mLModerate Hepatic ImpairmentHealthy Control
PK Parameter: Cmax of Filgotinib722.6 ± 293.24802.2 ± 485.98
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 115.98 · 90% CI 58.75 to 228.98
PrimaryPK Parameter: Cmax of GS-829845

Cmax is defined as the maximum observed concentration of drug. GS-829845 is the primary metabolite of filgotinib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of GS-829845
ng/mLModerate Hepatic ImpairmentHealthy Control
PK Parameter: Cmax of GS-829845972.5 ± 256.091122.6 ± 447.45
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy Control · Glsm ratio: 102.85 · 90% CI 60.12 to 175.98
SecondaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events
Time frame:
Day 1 up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
percentage of participantsModerate Hepatic ImpairmentHealthy Control
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events30.010.0
SecondaryPercentage of Participants Who Experienced Graded Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Day 1 up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
percentage of participantsModerate Hepatic ImpairmentHealthy Control
Any Laboratory Abnormality90.070.0
Grade 3 or 4 Laboratory Abnormalities60.00.0

Adverse events

Collected over Day 1 up to Day 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Hepatic Impairment0/10 (0%)0/10 (0%)3/10 (30%)
Healthy Control0/10 (0%)0/10 (0%)1/10 (10%)
Most frequent other events
Most frequent other events
EventModerate Hepatic ImpairmentHealthy Control
DiarrhoeaGastrointestinal disorders1/100/10
Chest discomfortGeneral disorders1/100/10
RhinitisInfections and infestations0/101/10
CoughRespiratory, thoracic and mediastinal disorders1/100/10
DyspnoeaRespiratory, thoracic and mediastinal disorders1/100/10
Rash papularSkin and subcutaneous tissue disorders1/100/10

Baseline characteristics

The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Moderate Hepatic ImpairmentHealthy ControlTotal
Mean61 ± 6.962 ± 5.361 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Moderate Hepatic ImpairmentHealthy ControlTotal
Female7714
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthy ControlTotal
Hispanic or Latino5510
Not Hispanic or Latino5510
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthy ControlTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101020
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Moderate Hepatic ImpairmentHealthy ControlTotal
New Zealand224
United States6612
Germany224
08

Study locations

4 sites
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • APEX GmbH
    Munich, 81241, Germany
  • Auckland Clinical Studies Ltd.
    Grafton, Auckland 1010, New Zealand
09

References and documents

Publications

  • Anderson K, Zheng H, Medzihradsky O, et al. THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT. Annals of the Rheumatic Diseases. 2019;78:331.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2018, 4 months.

Results were first posted in Jan 2021, 2 years 5 months after primary completion.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 4 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Jan 31, 2018
StartActual
Apr 3, 2018
Primary completionActual
Aug 9, 2018
CompletionActual
Aug 9, 2018
Results first posted
Jan 15, 2021
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03417778
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Apr 3, 2018
Primary completion
Aug 9, 2018
Completion
Aug 9, 2018
Results posted
Jan 15, 2021
Last update
Jan 15, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion